Neurocrine Biosciences, Inc. announced the publication of a narrative review in Expert Review of Endocrinology & Metabolism, discussing the challenges of traditional treatment for classic congenital adrenal hyperplasia (CAH) with glucocorticoids (GCs) alone. The review highlights the potential benefits of introducing novel non-GC mechanisms for treating the condition.
The publication emphasizes that the treatment of classic CAH is a lifelong challenge, requiring a balance between managing excess adrenocorticotropic hormone (ACTH) and androgens, historically achieved through high doses of GCs, while mitigating GC-related complications. Chronic exposure to high-dose GC treatment can result in severe cardiovascular, metabolic, and skeletal complications, as well as negatively impact mental health.
The review notes that CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, is the first and only classic CAH treatment that directly reduces excess ACTH and downstream adrenal androgen production, allowing for GC dose reduction. This offers a potential new paradigm for CAH management, aiming to reduce the risk of complications associated with high-dose steroids.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.